A Randomized Controlled Multicentered Phase 2/3 Study to Evaluate SHR-1210 (PD-1 Antibody) in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Failed or Intolerable to Prior Systemic Treatment
Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 02 Jan 2018
At a glance
- Drugs Camrelizumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 24 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 25 Sep 2017 Planned number of patients changed from 60 to 220.
- 14 Dec 2016 New trial record